Canaccord analyst Sumant Kulkarni said the weakness in Compass Pathways (CMPS) following the release of top-line results from its eagerly-awaited COMP005 Phase 3 trial for COMP360 (psilocybin) in treatment-resistant depression (TRD). COMP006, a second Phase 3 trial, is a buying opportunity. Canaccord believes updates from the FDA could eventually move the stock and there is no change tpo their model pending additional data. Canaccord reiterates its Buy rating and $15 price target on Compass Pathways shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways Achieves Phase 3 Trial Success
- Compass Pathways downgraded to In Line from Outperform at Evercore ISI
- Compass Pathways results ‘historic first’ for psychedelics, says H.C. Wainwright
- Compass Pathways weakness ‘significantly overdone,’ says Stifel
- Compass Pathways achieves primary endpoint in Phase 3 trial of COMP360